Get the Stockscreener App
48.66
1.28%
-0.63
After Hours:
48.85
0.19
+0.39%
Cytokinetics Inc stock is traded at $48.66, with a volume of 3.79M.
It is down -1.28% in the last 24 hours and up +28.59% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$49.29
Open:
$49.32
24h Volume:
3.79M
Relative Volume:
1.91
Market Cap:
$5.82B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-9.251
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
-4.83%
1M Performance:
+28.59%
6M Performance:
+11.99%
1Y Performance:
-12.48%
1-Day Range:
$47.96
$49.32
1-Week Range:
$47.34
$51.71
52-Week Range:
$29.31
$59.39
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
48.66 | 5.90B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics, Incorporated $CYTK Shares Acquired by Mirador Capital Partners LP - MarketBeat
Aug Breakouts: Is Cytokinetics Incorporated trading at a discount2025 Earnings Impact & Risk Adjusted Buy and Sell Alerts - khodrobank.com
Moving Averages: Is Blue Owl Capital Inc.’s ROE strong enough2025 Breakouts & Breakdowns & Verified Short-Term Plans - khodrobank.com
Cytokinetics (NASDAQ:CYTK) CEO Sells $248,850.00 in Stock - MarketBeat
E. Ohman J or Asset Management AB Buys 77,806 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Intech Investment Management LLC Raises Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17 - Bluefield Daily Telegraph
Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights – CYTK - GlobeNewswire Inc.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Cytokinetics, Incorporated (CYTK) Investors To Inquire About Securities Fraud Class Action - Business Wire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - Morningstar
CYTK STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cytokinetics, Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Cytokinetics, Incorporated Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 17, 2025 to Discuss Your RightsCYTK - PR Newswire
CYTK LAWSUIT ALERT: Levi & Korsinsky Notifies Cytokinetics, Incorporated InvestorsLead Plaintiff Deadline November 17, 2025 - ACCESS Newswire
Cytokinetics Investor Sues Over Heart Drug Approval Claims - Law360
Cytokinetics, Inc. Investigated by the Portnoy Lawfirm - GlobeNewswire
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
What are the future prospects of Cytokinetics IncorporatedTrade Entry Report & AI Enhanced Execution Alerts - khodrobank.com
CYTOKINETICS ALERT: Bragar Eagel & Squire, P.C. Announces - GlobeNewswire
Law Offices of Howard G. Smith Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire About Securities Fraud Class Action - MarketScreener
United Services Automobile Association Invests $331,000 in Cytokinetics, Incorporated $CYTK - MarketBeat
Investors Urged to Contact Levi & Korsinsky for Information Before November 17, 2025Cytokinetics, Incorporated (CYTK) - Newsfile
Cytokinetics, Incorporated (CYTK) LawsuitInvestors Urged to Contact Levi & Korsinsky Before November 17, 2025 - ACCESS Newswire
Cytokinetics announces inducement grants - MarketScreener
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Is Cytokinetics Incorporated affected by consumer sentimentMarket Trend Report & Fast Entry and Exit Trade Plans - khodrobank.com
Cytokinetics Investor Sues Over Heart Drug’s FDA Approval Delay - Bloomberg Law News
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - Bluefield Daily Telegraph
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has B - GuruFocus
Growth Value: Will Cytokinetics Incorporated outperform its industry peersQuarterly Portfolio Report & AI Based Trade Execution Alerts - khodrobank.com
Cytokinetics (CYTK) Drops on $650-Million Debt Issuance - Yahoo Finance
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Shareholders Filed a Lawsuit Against Cytokinetics for Misleading FDA Timeline - TradingView
Cytokinetics ($CYTK) Delayed Drug Review Due to Incomplete FDA Submission Case - TradingView
Cytokinetics to Present Key Findings on Aficamten at HFSA Annual Scientific Meeting 2025 - Quiver Quantitative
Cytokinetics announces three upcoming presentations at the HFSA Annual Scientific Meeting 2025 - MarketScreener
Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025 - Yahoo Finance
Levi & Korsinsky Notifies Cytokinetics, Incorporated (CYTK) Shareholders of Class Action Lawsuit and November 17, 2025 Deadline - ACCESS Newswire
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment stock outlook - Investing.com
Do you own shares of CYTK? Robbins LLP Informs Investors of the Cytokinetics, Inc. Class Action Lawsuit - PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Cytokinetics, Incorporated Common Stock and Sets a Lead Plaintiff Deadline of November 17, 2025 - GlobeNewswire
X4 Pharmaceuticals restructures; Cytokinetics targets $650M raise - Endpoints News
Cytokinetics (CYTK) Rises on Convertible Note Offering Plan - GuruFocus
Cytokinetics rises after upsized $650 mln convertible bonds sale - TradingView
Woodline Partners LP Grows Stock Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Prices Upsized $650 Million Private Convertible Notes Offering - MarketScreener
Cytokinetics Upsizes Convertible Notes Offering To $650 Mln - Nasdaq
Cytokinetics (CYTK) Boosts Convertible Note Offering to $650M - GuruFocus
Cytokinetics prices $650 million convertible notes offering By Investing.com - Investing.com Canada
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes - The Manila Times
Cytokinetics Inc prices its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 - MarketScreener
$650 Million Debt Refinancing: Cytokinetics Slashes Interest Rate to 1.75% in Strategic Note Offering - Stock Titan
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Sep 09 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
142,610 |
| Malik Fady Ibraham | EVP Research & Development |
Sep 09 '25 |
Sale |
51.29 |
2,000 |
102,580 |
140,610 |
| Kaye Edward M. MD | Director |
Sep 02 '25 |
Sale |
50.00 |
6,756 |
337,800 |
23,230 |
1.43%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):